Disclosed herein are reduced viscosity liquid formulations comprising a protein and an excipient compounds. Further disclosed are methods of reducing the viscosity of a liquid formulation comprising a protein, methods of treatment, and methods of improving protein processing.

Disclosed herein are reduced viscosity liquid formulations comprising a protein and an excipient compounds. Further disclosed are methods of reducing the viscosity of a liquid formulation comprising a protein, methods of treatment, and methods of improving protein processing.

Disclosed here is an adenosine derivative prodrug that can have reverse transcriptase inhibitor activity in vivo. This disclosure is also directed to a pharmaceutical composition comprising the adenosine derivative that can be used for the treatment of HIV infection or RNA virus infection.

A new stable formulation comprising efinaconazole and its process for preparing. The formulation of the present invention exhibits low levels of impurities.

A new stable formulation comprising efinaconazole and its process for preparing. The formulation of the present invention exhibits low levels of impurities.

Milk fat globule membrane (MFGM) phospholipid compositions, methods of preparing and using the MFGM phospholipid compositions, liposomes comprising the MFGM phospholipid compositions, and methods of preparing and using the liposomes comprising the MFGM phospholipid compositions. In various examples, a MFGM phospholipid composition is formed by sequential supercritical carbon dioxide (SC—CO.sub.2) extraction of a milk product and extraction of the remaining milk product with a polar compound-modified SC—CO.sub.2 extraction, where the extract is the MFGM. In various examples, the MFGM is used to prepare liposomes. In various examples, the liposomes are prepared by expansion of a supercritical solution comprising the MFGM composition. In various examples, the liposomes are used to administer a cargo, such as, for example, hydrophilic compound(s), hydrophobic compound(s), amphiphilic compound(s), or the like, any one or all of which may be therapeutic agent(s), nutrient(s), bioagent(s), or the like, or any combination thereof to a subject.

Milk fat globule membrane (MFGM) phospholipid compositions, methods of preparing and using the MFGM phospholipid compositions, liposomes comprising the MFGM phospholipid compositions, and methods of preparing and using the liposomes comprising the MFGM phospholipid compositions. In various examples, a MFGM phospholipid composition is formed by sequential supercritical carbon dioxide (SC—CO.sub.2) extraction of a milk product and extraction of the remaining milk product with a polar compound-modified SC—CO.sub.2 extraction, where the extract is the MFGM. In various examples, the MFGM is used to prepare liposomes. In various examples, the liposomes are prepared by expansion of a supercritical solution comprising the MFGM composition. In various examples, the liposomes are used to administer a cargo, such as, for example, hydrophilic compound(s), hydrophobic compound(s), amphiphilic compound(s), or the like, any one or all of which may be therapeutic agent(s), nutrient(s), bioagent(s), or the like, or any combination thereof to a subject.

The present disclosure relates to a compound of Formula (I)

##STR00001##

or a pharmaceutically acceptable salt thereof, which can be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid.

The present disclosure relates to a compound of Formula (I)

##STR00001##

or a pharmaceutically acceptable salt thereof, which can be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid.

Provided is an immunostimulator containing: chitosan and/or a chitosan derivative each having a weight-average molecular weight of 10k to 1000k; and an anionic surfactant, the immunostimulator being in particulate form. Also provided are a pharmaceutical composition and an alimentary product, each containing the immunostimulator as an active ingredient.